Brazilian Guidelines for the pharmacological treatment of patients hospitalized with COVID-19: Joint guideline of Associação Brasileira de Medicina de Emergência, Associação de Medicina Intensiva Brasileira, Associação Médica Brasileira, Sociedade Brasileira de Angiologia e Cirurgia Vascular, Sociedade Brasileira de Infectologia, Sociedade Brasileira de Pneumologia e Tisiologia, Sociedade Brasileira de Reumatologia.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Falavigna Maicon, Stein Cinara, Amaral José Luiz Gomes do, Azevedo Luciano Cesar Pontes de, Belli Karlyse Claudino, Colpani Verônica, Cunha Clóvis Arns da, Dal-Pizzol Felipe, Dias Maria Beatriz Souza, Ferreira Juliana Carvalho, Freitas Ana Paula da Rocha, Gräf Débora Dalmas, Guimarães Hélio Penna, Lobo Suzana Margareth Ajeje, Monteiro José Tadeu, Nunes Michelle Silva, Oliveira Maura Salaroli de, Prado Clementina Corah Lucas, Santos Vania Cristina Canuto, Silva Rosemeri Maurici da, Sobreira Marcone Lima, Veiga Viviane Cordeiro, Vidal Ávila Teixeira, Xavier Ricardo Machado, Zavascki Alexandre Prehn, Machado Flávia Ribeiro, Carvalho Carlos Roberto Ribeiro de
Аннотация
METHODS: A group of 27 experts, including representatives of the Ministry of Health and methodologists, created this guideline. The method used for the rapid development of guidelines was based on the adoption and/or adaptation of existing international guidelines (GRADE ADOLOPMENT) and supported by the e-COVID-19 RecMap platform. The quality of the evidence and the preparation of the recommendations followed the GRADE method.
RESULTS: Sixteen recommendations were generated. They include strong recommendations for the use of corticosteroids in patients using supplemental oxygen, the use of anticoagulants at prophylactic doses to prevent thromboembolism and the nonuse of antibiotics in patients without suspected bacterial infection. It was not possible to make a recommendation regarding the use of tocilizumab in patients hospitalized with COVID-19 using oxygen due to uncertainties regarding the availability of and access to the drug. Strong recommendations against the use of hydroxychloroquine, convalescent plasma, colchicine, lopinavir + ritonavir and antibiotics in patients without suspected bacterial infection and also conditional recommendations against the use of casirivimab + imdevimab, ivermectin and rendesivir were made.
CONCLUSION: To date, few therapies have proven effective in the treatment of hospitalized patients with COVID-19, and only corticosteroids and prophylaxis for thromboembolism are recommended. Several drugs were considered ineffective and should not be used to provide the best treatment according to the principles of evidence-based medicine and promote economical resource use.